Active	Status	Sponsor type	Region	Phase	Filter
6 Active 3 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Marshall, Catherine
NCT03047135: Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	Active, not recruiting	2	51	US	Olaparib	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca	Prostate	05/23	05/25
NCT04126070: Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors	Active, not recruiting	2	60	US	Androgen Deprivation Therapy, Leuprolide, Lupron Depot, Goserelin acetate, Zoladex, Degarelix, Firmagon, Nivolumab, Docetaxel, Taxotere	Xiao X. Wei, MD, Bristol-Myers Squibb	Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma	10/24	06/25
Barrios, Macy
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults	Completed	2/3	125	Canada, US	LAU-7b, fenretinide, Placebo oral capsule	Laurent Pharmaceuticals Inc.	COVID-19 Disease	02/24	05/24